Breaking News
February 20, 2019 - CVD Does Not Modify Depression-Mortality Link in Elderly
February 20, 2019 - Electrical activity early in fruit flies’ brain development could shed light on how neurons wire the brain
February 20, 2019 - Self-reported sleep duration is a useful tool to measure sleep in children, study suggests
February 20, 2019 - T-cells play key role in how the body fights follicular lymphoma
February 20, 2019 - Study shows how 3D organization of genetic material helps perpetuate the species
February 20, 2019 - Researchers engineer stem cell with ‘suicide genes’ to induce cell death in all but beta cells
February 20, 2019 - Study reveals major sex differences in management of cardiovascular risk factors among U.S. adults
February 20, 2019 - Health Tip: Get Your Child to School on Time
February 20, 2019 - Shortcut strategy for screening compounds with clinical potentials for drug development
February 20, 2019 - Common acid reflux drugs tied to elevated risk for kidney disease
February 20, 2019 - Microbiome could be culprit when good drugs do harm
February 20, 2019 - Prenatal exposure to forest fires causes stunted growth in children
February 20, 2019 - Gene therapy restores hearing in mice with congenital genetic deafness
February 20, 2019 - First molecular test predicts treatment response for kidney cancer
February 20, 2019 - New method for improved visualization of single-cell RNA- sequencing data
February 20, 2019 - Researchers capture altered brain activity patterns of Parkinson’s in mice
February 20, 2019 - A possible blood test for detecting Alzheimer’s disease before symptoms show
February 20, 2019 - Primary care physicians associated with longevity, new research finds
February 19, 2019 - New study identifies many key lessons to establish sanctioned safe consumption sites
February 19, 2019 - Single CRISPR treatment can safely and stably correct genetic disease
February 19, 2019 - Multinational initiative to study familial primary distal renal tubular acidosis
February 19, 2019 - Breakthrough study highlights the promise of cell therapies for muscular dystrophy
February 19, 2019 - Subsymptom Threshold Exercise Speeds Concussion Recovery
February 19, 2019 - Midline venous catheters – infants: MedlinePlus Medical Encyclopedia
February 19, 2019 - Searching for side effects
February 19, 2019 - Humanity is all right, probably, although human extinction remains quite possible, researcher says
February 19, 2019 - Having Anesthesia Once as a Baby Does Not Cause Learning Disabilities, New Research Shows
February 19, 2019 - Anti-cancer immunotherapy could be used to fight HIV
February 19, 2019 - Customized Micropatterning for Improved Physiological Relevance
February 19, 2019 - Unique gene therapy approach paves new way to tackle rare, inherited diseases
February 19, 2019 - Activating gene that helps excite neurons reverses depression in male mice
February 19, 2019 - Science Puzzling Out Differences in Gut Bacteria Around the World
February 19, 2019 - Cells that destroy the intestine
February 19, 2019 - On recovery, vulnerability and ritual: An exhibit in white
February 19, 2019 - Scientific Duo Gets Back To Basics To Make Childbirth Safer
February 19, 2019 - COPD patients need more support when understanding new chest symptoms
February 19, 2019 - Using light-based method for production of pharmaceutical molecules
February 19, 2019 - Scientists find link between inflammation and cancer
February 19, 2019 - The High Cost Of Sex: Insurers Often Don’t Pay For Drugs To Treat Problems
February 19, 2019 - Hearing impairment associated with accelerated cognitive decline with age
February 19, 2019 - Researchers identify multiple genetic variants associated with body fat distribution
February 19, 2019 - Influenza and common cold are completely different diseases, study shows
February 19, 2019 - Scientists untangle how microbes manufacture key antibiotic compound
February 19, 2019 - Greater primary care physician supply associated with longer life spans
February 19, 2019 - HIV-1 protein suppresses immune response more broadly than thought
February 19, 2019 - Brain imaging indicates potential success of drug therapy in depressive patients
February 19, 2019 - For 2020 Dem Hopefuls, ‘Medicare-For-All’ Is A Defining Issue, However They Define It
February 19, 2019 - Specialized lung cells appear in the developing fetus much earlier than previously thought
February 19, 2019 - KU professor discusses promise of brain-computer interface to aid, restore communication
February 19, 2019 - Highly effective solution for detecting onset of aggregation in nanoparticles
February 19, 2019 - Early marker of cardiac damage triggered by cancer treatment identified
February 19, 2019 - Antidepressant drug could save people from deadly sepsis, research suggests
February 19, 2019 - CRISPR technology creates pluripotent stem cells that are ‘invisible’ to the immune system
February 19, 2019 - New study establishes how stress favors breast cancer growth and spread
February 19, 2019 - Midlife Systemic Inflammation Linked to Later Cognitive Decline
February 19, 2019 - Therapy derived from parasitic worms downregulates proinflammatory pathways
February 19, 2019 - Antimicrobial reusable coffee cups are less likely to become contaminated with bacteria, study shows
February 19, 2019 - Harnessing the evolutionary games played by cancer cells to advance therapies
February 19, 2019 - AHA News: Heart Transplant Survivor Gets Wedding Proposal at Finish Line
February 19, 2019 - HIV hidden in patients’ cells can now be accurately measured
February 19, 2019 - Research finds reasons for sudden cardiac death in patients with stable ischemic disease
February 19, 2019 - New protocol could help physicians to rule out bacterial infections in infants
February 19, 2019 - Women experiencing miscarriage should be offered treatment choices
February 19, 2019 - New protocol can help identify febrile infants at low risk for serious bacterial infections
February 19, 2019 - Innovative way to block HIV runs into a roadblock
February 19, 2019 - Springer Nature with BCRF conduct pilot project to make their research datasets more accessible
February 19, 2019 - Study finds neuromelanin-sensitive MRI as potential biomarker for psychosis
February 19, 2019 - Improvements in cardiovascular care for elderly save billions in health care costs
February 19, 2019 - Chilean food regulations are changing food perceptions and purchasing habits, study suggests
February 19, 2019 - Index endoscopy results are crucial for assessment of Barrett’s patients
February 18, 2019 - Breast cancer screening age should be lowered to 35
February 18, 2019 - Brain synchronization depends on the language of communication
February 18, 2019 - Drug Company Payments Over Time May Influence Rx Practices
February 18, 2019 - Despite socioeconomic gains, black-white ‘health gap’ remains
February 18, 2019 - Researchers report progress in the treatment of aggressive brain tumors
February 18, 2019 - Scientists discover trigger that turns strep infections into devastating disease
February 18, 2019 - Scanning children’s teeth may predict future mental health issues
February 18, 2019 - Health Highlights: Feb. 14, 2019
February 18, 2019 - New knowledge could help predict and prevent depression
February 18, 2019 - More primary care physicians leads to longer life spans | News Center
Precision medicine offers a glimmer of hope for Alzheimer’s disease

Precision medicine offers a glimmer of hope for Alzheimer’s disease

image_pdfDownload PDFimage_print
PET scan of a human brain with Alzheimer’s disease. Credit: public domain

The decadeslong search for effective ways to treat or prevent Alzheimer’s disease is littered with failures, leaving 5.7 million Americans already stricken with this form of dementia without a lifeline. The rest of us are left to hope we won’t be among the 1 in 10 over 65 who gets the devastating diagnosis.

But precision medicine—an approach that is changing the treatment of cancer and spawning targeted therapies for a wide range of diseases—may open new avenues for the treatment of Alzheimer’s disease. And new ways to test experimental treatments promise to more quickly identify treatments that work, and perhaps the patients in whom they will work best.

This week, dementia specialists gathered at the Alzheimer’s Association’s International Conference in Chicago to assess the state of the field. And researchers gleaned some glimmers of real hope in both precision medicine and innovative trial designs to deliver new treatments for Alzheimer’s disease.

These approaches raised expectations that at least two experimental drugs—one called BAN2401 and the other Anavex 2-73—might successfully treat some with Alzheimer’s.

In the case of BAN2401, the successful preliminary finding of a trial that enrolled 856 patients with early Alzheimer’s disease has breathed new life into a hypothesis that persists despite withering failures: that reducing clumps of proteins called amyloid plaques that accumulate in the brains of those with Alzheimer’s might slow or reverse their symptoms of memory loss and cognitive confusion.

Using an innovative clinical trial design, the U.S. and Japanese companies developing BAN2401 found that over 18 months of treatment, patients who got the highest doses of the medication had dramatic reductions in amyloid plaque deposits in their brains. And compared with subjects who got a placebo, those who got the highest dose showed a 26 percent slowing of clinical decline after 18 months.

As the trial of BAN2401 progressed, its “adaptive design” ensured that when new subjects were recruited, they were more likely to be assigned to arms of the trial that showed the greatest promise. While considered controversial by some researchers, clinical trial designs that flex to seize upon promising preliminary findings have a high-level supporter in the Trump administration’s Food and Drug Administration: Commissioner Scott Gottlieb.

“Alzheimer’s disease trials need to evolve,” said James A. Hendrix, director of global science initiatives at the Alzheimer’s Association. “We need to try new things and learn from other diseases,” he added, including fields such as cancer, where for select subsets of patients, new targeted therapies are delivering cures.

Distinguishing between likely responders and those not likely to be helped by a medication first, said Hendrix, “is an exciting new way to think about” new treatments for Alzheimer’s. “Maybe one-size-fits-all is not the best approach,” he added.

In a first-ever bid to apply the principles of precision medicine to Alzheimer’s disease, researchers also reported this week on a small study of Alzheimer’s patients who bear a few “actionable genetic variants.” In these patients, they found, Anavex 2-73 appeared to slow and perhaps even reverse early cognitive decline.

The new findings emerged from a clinical trial designed to test the safety of Anavex 2-73, and it involved just 32 patients with mild to moderate Alzheimer’s. So it’s far too early to tout the success of this experimental drug.

But researchers built an extra step into their safety trial: sequencing the subjects’ genomes. In doing so, they hoped to find genomic signatures in some patients that would make them more likely to respond positively to the drug.

While the researchers combed through more than 33,000 genes, they had a pretty good picture of what molecular processes (or pathways) Anavex 2-73 worked on. So they knew what they were looking for: gene variations that were likely to interfere with the actions of Anavex 2-73 and make treatment unsuccessful. They found two such genetic variants, present in about one-fifth of humans.

When researchers from Anavex narrowed the subject pool to just those patients whose genetic makeup was compatible with its mode of action, they found that subjects who got the medication for 57 weeks experienced “clinically meaningful” improvements in their ability to reason, remember and carry on daily activities.

A larger new trial on subjects with Alzheimer’s is set to begin in Australia and North America. The experimental medication is also being tested as a possible treatment for dementia associated with Parkinson’s disease, for Rett syndrome and for Fragile X syndrome.

The idea that a medication to treat Alzheimer’s disease might work well in some dementia patients and not as well in others is consistent with a growing sense, first, that Alzheimer’s may be many different diseases. But it also fits with the notion that genetic factors—acting alone or collectively—predispose some to Alzheimer’s while protecting others.

In precision medicine, sometimes called personalized medicine, researchers work to identify the genetic factors that drive or contribute to a disease and build medicine that targets the downstream effects of those miscreant genes. Then, they use genomic sequencing technologies to identify just those patients who bear the distinctive genetic signatures their drug works on. More often than not, these drugs are costly, and they don’t work on everyone. But when the right patients get the right medicine at the right time, treatments will be more effective and have fewer side effects.

“If you include a biomarker, which can be detected in a matter of hours or days by a swab test, then you can enrich a study—enroll just the subjects most likely to respond—and of course, improve the chances of success,” said Christopher Missling, a founding director of Anavex Life Sciences Corp.

Such new approaches to treating dementia could turn the tide in the discouraging search for Alzheimer’s treatments, said Dr. Deepak Bhatt, an expert on adaptive trial designs and precision medicine.

“Identifying which patients might benefit from a novel therapy using biomarkers or genetics will likely be a big part of how medicine is individualized in the future—so-called precision medicine,” said Bhatt, who directs interventional cardiovascular programs at Brigham and Women’s Hospital in Boston.

“This approach may be especially well suited for therapies that might have side effects or are expensive. While further confirmatory studies are needed for this particular Alzheimer’s drug before clinical use, the potential of personalizing care for such a devastating disease is exciting. ”


Explore further:
Alzheimer’s drug trial offers new hope, but uncertainty, too

Tagged with:

About author

Related Articles